上海交通大学医学院附属仁济医院肿瘤科主任、肿瘤临床药物试验基地主任，上海交通大学专科医师培训基地专家组组长。上海交通大学胰腺癌诊治中心主任，上海胰腺疾病重点实验室副主任。2001.9-2002.1在美国加州大学洛杉矶分校（UCLA）做高级访问。2002.1-2004.6在美国MD Anderson癌症中心任客座教授。2012年获上海市优秀学科带头人，2017年获上海市领军人才。现任中国临床肿瘤学会(CSCO)胰腺癌专家委员会主任委员，主持制定了中国临床肿瘤学会第一个《胰腺癌综合诊治中国专家共识》。任中华医学会肿瘤学分会委员、上海医学会肿瘤专科分会副主任委员、中国研究型医院学会胰腺疾病专委会副主任委员。科技部成果评审专家、教育部博士后基金评审专家、国家自然基金评审专家、CFDA新药评审专家、CSCO执行委员会委员、中国医师协会肿瘤分会全国委员、中国肿瘤驱动基因联盟（CAGC）执行委员会常委、中国生物医学工程学会肿瘤靶向治疗技术分会常委、中国医药技术协会精准医疗分会常委、中国医师协会胰腺病委员会委员、上海市胃肠肿瘤专业委员委员、上海市化疗质控中心专家委员会委员、上海市抗癌协会理事、美国癌症研究协会（AACR）正式会员、美国临床肿瘤学会（ASCO）正式会员，担任《Cancer Research》、《肿瘤》、《中华肿瘤防治杂志》、《临床肿瘤学杂志》、《肿瘤学杂志》、《肿瘤防治研究》等编委。多次主持或参加国际及国内多中心I/II/III期临床研究，先后主持国家自然科学基金重大研发计划、国家自然科学基金、上海市科委基金等多项课题。 2003年在国际上首先报道了转录因子Sp1与胃癌生存之间的关系，2010年首次研究发现胰腺癌治疗的新靶点，发现两种小分子抑制剂联合作用可抑制胰腺癌的进展，该研究已申请国家新药发明专利；2012年获国家自然科学基金重大研究计划“非可控性炎症恶性转化的调控网络及其分子机制”资助，该项目为首个获得立项的胰腺炎症恶性转化国家级课题。在《Lancet Oncology》 《Journal of Clinical Oncology》《Cancer Research》《Gastroenterology》《Clinical Cancer Research》等杂志上发表了系列临床及转化研究文章，他引次数超过1000余次。

课题组聚焦肿瘤精准诊疗，具体研究方向包括：

1.临床前及I/II/III期新药临床研究

2.肿瘤特异性免疫治疗和细胞治疗

3.PDX模型及药效评估体系，生物标志物的筛选和发现

4.肿瘤免疫微环境与炎癌恶性转化机制

1.      Hu H, Li H, Jiao F, Han T, Zhuo M, Cui J, Li Y, Wang L. Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. J Hematol Oncol. 2017 Oct 3;10(1):158. doi: 10.1186/s13045-017-0523-y.

2.      Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016;34:1448-1454.

3.      Liu L, Xiang J, Chen R, Fu D, Hong D, Hao J, Li Y, Li J, Li S, Mou Y, Mai G, Ni Q, Peng L, Qin R, Qian H, Shao C, Sun B, Sun Y, Tao M, Tian B, Wang H, Wang J, Wang L, Wang W, Wang W, Zhang J, Zhao G, Zhou J, Yu X. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol 2016;48:900-907.

4.      Han T, Jiao F, Hu H, Yuan C, Wang L, Jin ZL, Song WF, Wang LW. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer. Oncotarget 2016.

5.      Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L, Wang L. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 2016.

6.      Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, Jin Z, Wang L, Wang Y, Wang L. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Med Oncol,32(5):589, 2015.

7.      Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells. Int J Mol Sci,16(4):6677-6693, 2015.

8.      Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619-629.

9.      Hang J, Cai B, Xue P, Wang L, Hu H, Zhou Y, Ren S, Wu J, Zhu M, Chen D, Yang H, Wang L. The Joint Effects of Lifestyle Factors and Comorbidities on the Risk of Colorectal Cancer: A Large Chinese Retrospective Case-Control Study. PLoS One 2015;10:e143696.

10.   Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol, 2015.

11.   Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric  cancer patients. Surg Oncol,24(3):220-225, 2015.

12.   Song W, Li Q, Wang L, Huang W, Wang L. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci Rep,5:10081, 2015.

13.   Song W, Li Q, Wang L, Wang L. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem,35(1):184-190, 2015.

14.   Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z, Wang L. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth,  migration and invasion in pancreatic cancer. Oncol Rep,32(6):2485-2492, 2014.

15.   Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013;31:3219-3225.

16.   Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol,139(9):1579-1589, 2013.

17.   Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res,73(13):3987-3996, 2013.

18.   Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon C D, Le X, Wei D, Huang S, Xie K. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res,72(3):655-665, 2012.

19.   Jiang W, Cui J, Xie D, Wang L. Sp/KLF family and tumor angiogenesis in pancreatic cancer. Curr Pharm Des,18(17):2420-2431, 2012. (IF:4.414)

20.   Gao Y, Jia Z, Kong X, Li Q, Chang D Z, Wei D, Le X, Suyun H, Huang S, Wang L, Xie K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res,71(15):5182-5193, 2011.

21.   Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K.. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010;70(3):1111-1119

22.   Wei D,Wang L, Kanai M, Jia Z, Le X, Li Q, Wang H, Xie K KLF4alpha Upregulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients with Pancreatic Cancer. Gastroenterology 2010;139(6):2135-45